Theravance Biopharma (TBPH) EPS (Diluted) (QoQ) (2018 - 2026)
Theravance Biopharma (TBPH) EPS (Diluted) (QoQ) (2018 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | Theravance Biopharma | 864.82 Mn | 470.15 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -117.43% |
| Dec 31, 2025 | 698.65% |
| Sep 30, 2025 | -93.56% |
| Jun 30, 2025 | 495.70% |
| Mar 31, 2025 | 14.06% |
| Dec 31, 2024 | -22.76% |
| Sep 30, 2024 | 23.63% |
| Jun 30, 2024 | -40.36% |
| Mar 31, 2024 | -151.93% |
| Dec 31, 2023 | 43.90% |
| Sep 30, 2023 | 38.07% |
| Jun 30, 2023 | 19.91% |
| Mar 31, 2023 | -751.27% |
| Dec 31, 2022 | -99.57% |
| Sep 30, 2022 | 4,994.73% |
| Jun 30, 2022 | 16.29% |
| Mar 31, 2022 | -44.17% |
| Dec 31, 2021 | 32.54% |
| Sep 30, 2021 | 47.69% |
| Jun 30, 2021 | 79.53% |